We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Code Biotherapeutics Stock

Invest in or calculate the value of your shares in Code Biotherapeutics or other pre-IPO companies through EquityZen's platform.

Get Started

Code Biotherapeutics Stock (COBI)

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.

About Code Biotherapeutics Stock

Founded

2020

Headquarters

Hatfield, PA, US

Industries

Software, Data and Analytics, Artificial Intelligence

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Code Biotherapeutics Press Mentions

Stay in the know about the latest news on Code Biotherapeutics

Code Biotherapeutics Management

Leadership team at Code Biotherapeutics

COO

Erin Brubaker

Chairman, Chief Executive Officer, and Co-Founder

Brian McVeigh

Locked Features

Join now and verify your accreditation status to gain access to:

  • Code Biotherapeutics current valuation
  • Code Biotherapeutics stock price
  • Available deals in Code Biotherapeutics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Code Biotherapeutics stock?

Accredited investors can buy pre-IPO stock in companies like Code Biotherapeutics through EquityZen funds. These investments are made available by existing Code Biotherapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Code Biotherapeutics stock?

Shareholders can sell their Code Biotherapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."